• A recent systematic literature review of randomized controlled dermatology-related trials showed that patient-reported outcomes (PROs) were mentioned in some form in only 25.6% of 125 trials conducted from 1994 to 2001.
• For example, in a noninterventional prospective trial conducted in Germany, 579 patients with psoriasis were treated with a once-daily fi xed combination of calcipotriol 50 µg/g plus betamethasone 0.5 mg/g (Daivobet gel) for 4 weeks, and Daivobet gel was compared with prior therapy.
• PROs were assessed using the Dermatology Life Quality Index (DLQI), Psoriasis Disability Index (PDI), Patient Global Assessment of disease severity (PGA) (range, 0-5), and questions on how easy the new medication was to use.
-Patient burden: As assessed by the PDI, patient burden was decreased when taking Daivobet gel compared with prior therapy (Figure 1 ).
-Disease severity: As judged by patients, 83.6% had moderately severe, severe, or very severe involvement at baseline; at the end of the study, only 25.5% were in these categories. Overall, 85.7% of patients were very satisfi ed or satisfi ed with the e cacy of Daivobet gel, while only 27.6% of the patients were very satisfi ed or satisfi ed with prior topical treatment.
-Tolerability: 75.4% of patients were very satisfi ed with Daivobet gel, and 29.5% were very satisfi ed with prior treatment. 
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Prescribers
• Comparative trials evaluating the dermatology drugs reviewed reported PRO data information on each product's benefi ts and risks, and also which product was superior from the patient perspective.
• For example, Ortonne and colleagues (2009) 3 conducted an 8-week, randomized, investigator-blind study in 17 centers in fi ve countries (Belgium, Canada, Denmark, France, and Sweden) comparing the once-daily, two-compound scalp formulation of calcipotriol 50 µg/g and betamethasone 0.5 mg/g (Xamiol gel) with twice-daily calcipotriol (50 µg/g) (Daivonex).
• PROs were assessed using the 36-Item Short Form Health Survey (SF-36) and the Skindex-16.
Regulators and Manufacturers
• For regulators, PROs were included in the product label for all except one of the six products reviewed (Table 1) . Similarly, for the manufacturer, the PRO data generated label claims and many publications that allowed extensive public dissemination of product benefi ts.
• PRO label claims were granted by the FDA for Atopiclair, Botox, pimecrolimus, tacrolimus, and ustekinumab. PRO claims were granted by the EMA for Botox, pimecrolimus, tacrolimus, and ustekinumab. 4 The types of PRO claims obtained for the drugs reviewed were as follows:
-Symptom (e.g., itching, burning, pain) (n = 4); Atopiclair (FDA), pimecrolimus (FDA and EMA), tacrolimus (FDA and EMA), ustekinumab (FDA and EMA)
-Interference with daily activities (n = 1): Botox (FDA and EMA) 2009 "Baseline disease characteristics were generally consistent across all treatment groups in Psoriasis Studies 1 and 2 with… median DLQI range from 10 to 12." "In Psoriasis Study 1, at week 2 and week 12, signifi cantly greater improvements from baseline were demonstrated in the DLQI in each ustekinumab treatment group compared with placebo. The improvement was sustained through week 28." "Similarly, signifi cant improvements were seen in Psoriasis Study 2 at week 4 and 12, which were sustained through week 24. In Psoriasis Study 1, improvements in nail psoriasis (Nail Psoriasis Severity Index), in the physical and mental component summary scores of the SF-36 and in the Itch VAS were also signifi cant in each ustekinumab treatment group compared with placebo. In Psoriasis Study 2, the HADS and WLQ were also signifi cantly improved in each ustekinumab treatment group compared with placebo." 
Payers
• For payers, utility values based on PROs were used in coste ectiveness evaluations for two of the six products for three indications.
-Tacrolimus ointment for regular and maintenance treatment of moderate-to-severe atopic dermatitis -Pimecrolimus for treatment of mild and moderate atopic dermatitis
DISCUSSION
• For all the dermatology drugs reviewed, inclusion of PROs in the clinical development program provided evidence of treatment benefi ts to patients, prescribers, regulators, manufacturers, and payers.
• Drug manufacturers of developmental drugs for atopic dermatitis, hyperhidrosis, and psoriasis should consider including the following:
-PRO measures meeting FDA PRO guidance criteria 4 to support PRO labeling claims for their products, both in the US and EU -PRO measures (e.g., EQ-5D) that produce utility values for use in cost-e ectiveness models and may facilitate reimbursement
CONCLUSION
• Including patient-reported assessment of the treatment impact on disease during development of dermatology drugs has many benefi ts for all stakeholders. 
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